CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs (Q45839644)

16 December 2017

title

CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs (English)

1 reference

16 December 2017

CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference Drugs (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1124/DMD.110.037911

26 November 2024

main subject

adverse drug reaction

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21383203

cytochrome P-450 CYP3A inhibitors

26 November 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21383203

26 November 2024

Alfred Zimmerlin

1 reference

16 December 2017

Markus Trunzer

series ordinal

1 reference

16 December 2017

Bernard Faller

series ordinal

1 reference

16 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21383203

26 November 2024

publication date

7 March 2011

1 reference

16 December 2017

full work available at URL

https://syndication.highwire.org/content/doi/10.1124/dmd.110.037911

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1124/DMD.110.037911

Drug Metabolism and Disposition

26 November 2024

published in

1 reference

16 December 2017

volume

1 reference

16 December 2017

issue

1 reference

16 December 2017

page(s)

1039-1046

1 reference

16 December 2017

Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis

cites work

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mechanism-based inhibition of human cytochrome P4503A4 by domperidone

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Role of itraconazole metabolites in CYP3A4 inhibition

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Drug-drug interactions of new active substances: mibefradil example

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Drugs as CYP3A probes, inducers, and inhibitors

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Differential behavior of the sub-sites of cytochrome 450 active site in binding of substrates, and products (implications for coupling/uncoupling).

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Effects of organic solvents on the time-dependent inhibition of CYP3A4 by diazepam

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Summary of information on human CYP enzymes: human P450 metabolism data

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

26 November 2024

1 reference

https://api.crossref.org/works/10.1124/DMD.110.037911

26 November 2024

Identifiers

DOI

1 reference

16 December 2017

1 reference

16 December 2017